Literature DB >> 14511294

On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome.

K Steen Carlsson1, S Höjgård, A Glomstein, S Lethagen, S Schulman, L Tengborn, A Lindgren, E Berntorp, B Lindgren.   

Abstract

Using an 11-year panel of 156 Norwegian and Swedish patients with severe haemophilia, and including retrospective case-book data from birth, we compared the differences in the haemophilia-related resource use between on-demand and prophylactic treatment. Patients treated on-demand had more surgery (arthrodeses, prostheses implantations and synovectomies) and more days lost from work. Median annual factor-concentrate consumption among adults (18+) was 211,000 IU [interquartile range (IQR) 154,000-268,000] or 3,024 IU kg-1 year(-1) for patients on prophylactic treatment and 55,000 IU (IQR 28,000-91,000) for on-demand patients (780 IU kg(-1) year(-1)). This was partly explained by the fact that the median dose per kg body weight was twice as great 28, (IQR 24-32) for prophylaxis compared with 14 (IQR 12-16) for on-demand. Prescribed dose per kg body weight was found to be an important factor explaining the variation in total annual factor-concentrate consumption per patient for both types of treatment. Other variables included in the panel-data regression analysis were the number of weeks on secondary prophylaxis for on-demand patients and age, body weight and type of haemophilia for children (0-17 years) on prophylaxis. Differences were consistently substantial and will affect both costs and benefits of the two treatment strategies.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14511294     DOI: 10.1046/j.1365-2516.2003.00817.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  9 in total

1.  6 Factor VIII Concentrates, Factor VIII/von Willebrand Factor Concentrates, Factor IX Concentrates, Activated Prothrombin Complex Concentrates.

Authors: 
Journal:  Transfus Med Hemother       Date:  2009       Impact factor: 3.747

Review 2.  Low Dose Prophylaxis in Hemophilia Care.

Authors:  Neeraj Sidharthan; Remya Sudevan
Journal:  Indian J Hematol Blood Transfus       Date:  2019-06-15       Impact factor: 0.900

Review 3.  Extended Half-Life Factor VIII and Factor IX Preparations.

Authors:  Lukas Graf
Journal:  Transfus Med Hemother       Date:  2018-03-21       Impact factor: 3.747

4.  The social burden and quality of life of patients with haemophilia in Italy.

Authors:  Yllka Kodra; Marianna Cavazza; Arrigo Schieppati; Marta De Santis; Patrizio Armeni; Romano Arcieri; Gabriele Calizzani; Giovanni Fattore; Lamberto Manzoli; Lorenzo Mantovani; Domenica Taruscio
Journal:  Blood Transfus       Date:  2014-04       Impact factor: 3.443

Review 5.  Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A.

Authors:  Hans-Christoph Rossbach
Journal:  Vasc Health Risk Manag       Date:  2010-03-03

6.  Intermediate-dose versus high-dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s.

Authors:  Kathelijn Fischer; Katarina Steen Carlsson; Pia Petrini; Margareta Holmström; Rolf Ljung; H Marijke van den Berg; Erik Berntorp
Journal:  Blood       Date:  2013-06-18       Impact factor: 22.113

7.  Social/economic costs and quality of life in patients with haemophilia in Europe.

Authors:  Marianna Cavazza; Yllka Kodra; Patrizio Armeni; Marta De Santis; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Arrigo Schieppati; Georgi Iskrov; László Gulácsi; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-05

8.  [Efficacy of short-term full-dose prophylaxis in adult Chinese patients with severe hemophilia A].

Authors:  Xueyan Sun; Jinmu Zhuang; Xuan Zhou; Huiping Li; Zhuqin Liu; Jing Sun
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2018-09-30

9.  Persons with Haemophilia in Sweden- Experiences and Strategies in Everyday Life. A Single Centre Study.

Authors:  Elisabeth Brodin; Katharina S Sunnerhagen; Fariba Baghaei; Marie Törnbom
Journal:  PLoS One       Date:  2015-10-02       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.